HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV) Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| ATL-1102 | ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Multiple Sclerosis; Muscular Dystrophy, Duchenne | Details |
| BIIB-107(Biogen) | BIIB-107 | Phase 1 Clinical | Biogen Inc | Multiple Sclerosis | Details |
| ELND-004 | ELND-004 | Phase 1 Clinical | Perrigo Company Plc | Autoimmune Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Natalizumab biosimilar(Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Crohn Disease; Multiple Sclerosis | Sandoz Inc | 2023-08-24 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease | Details |